JP2010512407A - 新生物を処置するための組成物および方法 - Google Patents

新生物を処置するための組成物および方法 Download PDF

Info

Publication number
JP2010512407A
JP2010512407A JP2009541425A JP2009541425A JP2010512407A JP 2010512407 A JP2010512407 A JP 2010512407A JP 2009541425 A JP2009541425 A JP 2009541425A JP 2009541425 A JP2009541425 A JP 2009541425A JP 2010512407 A JP2010512407 A JP 2010512407A
Authority
JP
Japan
Prior art keywords
vegf
antibody
thalidomide
patient
relapsed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009541425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512407A5 (enExample
Inventor
ロバート ディー． マス
グレゴリー ディー． プラウマン
Original Assignee
ジェネンテック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック インコーポレイテッド filed Critical ジェネンテック インコーポレイテッド
Publication of JP2010512407A publication Critical patent/JP2010512407A/ja
Publication of JP2010512407A5 publication Critical patent/JP2010512407A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009541425A 2006-12-11 2007-05-04 新生物を処置するための組成物および方法 Pending JP2010512407A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (2)

Publication Number Publication Date
JP2010512407A true JP2010512407A (ja) 2010-04-22
JP2010512407A5 JP2010512407A5 (enExample) 2012-06-14

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541425A Pending JP2010512407A (ja) 2006-12-11 2007-05-04 新生物を処置するための組成物および方法

Country Status (17)

Country Link
US (1) US20100086544A1 (enExample)
EP (1) EP2099489B1 (enExample)
JP (1) JP2010512407A (enExample)
KR (1) KR101320198B1 (enExample)
CN (1) CN101547705B (enExample)
AU (1) AU2007333565A1 (enExample)
BR (1) BRPI0717688A2 (enExample)
CA (1) CA2670707A1 (enExample)
DK (1) DK2099489T3 (enExample)
IL (1) IL198852A (enExample)
MX (1) MX2009006202A (enExample)
NZ (1) NZ577058A (enExample)
RU (1) RU2482877C2 (enExample)
SG (1) SG177891A1 (enExample)
SI (1) SI2099489T1 (enExample)
WO (1) WO2008073509A2 (enExample)
ZA (1) ZA200903489B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2655334B1 (en) * 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
CN104244934A (zh) * 2012-03-14 2014-12-24 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
BR112017027798B1 (pt) 2015-07-27 2023-12-19 Chong Kun Dang Pharmaceutical Corp Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
HRP20230052T1 (hr) 2015-07-27 2023-03-03 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
NZ739211A (en) 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
HRP20220003T1 (hr) 2015-08-04 2022-04-01 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
FI3362445T3 (fi) 2015-10-12 2023-03-21 Chong Kun Dang Pharmaceutical Corp Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CN113874369B (zh) 2019-05-31 2024-08-27 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑高邻苯二甲酰亚胺衍生化合物及包含其的药物组合物
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012359A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Anti-vegf antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
CN1319090A (zh) * 1998-09-25 2001-10-24 贝林格尔英格海姆法玛公司 新的取代的二氢吲哚酮、它们的制备方法和它们作为药物的用途
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012359A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Anti-vegf antibodies

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BRUCKNER,H.W. ET AL, ANTICANCER RESEARCH, vol. 25, no. 5, JPN6012029579, 2005, pages 3637 - 9, ISSN: 0002246337 *
BURSTEIN,H.J. ET AL: "Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory", BREAST CANCER RESEARCH AND TREATMENT, vol. 76, JPN6013030893, 2002, pages 115, ISSN: 0002565512 *
CAMPBELL,R.A. ET AL, INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 28, no. 6, JPN6012029585, June 2006 (2006-06-01), pages 1409 - 1417, ISSN: 0002246339 *
CHAUHAN,D. ET AL, BLOOD, vol. 104, no. 8, JPN6012029582, 2004, pages 2458 - 2466, ISSN: 0002246338 *
CHEN,H.X. ET AL, JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 21, JPN6013030888, July 2006 (2006-07-01), pages 3354 - 3360, ISSN: 0002565515 *
D'ADAMO,D.R. ET AL, JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 28, JPN6013030885, 2005, pages 7135 - 7142, ISSN: 0002565513 *
DENZ,U. ET AL, EUROPEAN JOURNAL OF CANCER, vol. 42, no. 11, JPN6012029577, July 2006 (2006-07-01), pages 1591 - 600, ISSN: 0002246336 *
FRIEDMAN,H.S.: "Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment", ONCOLOGY REPORT, vol. Vol.Fall, JPN6013030895, September 2006 (2006-09-01), pages 11, ISSN: 0002565516 *
HERBST,R. ET AL: "A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizuma", EJC SUPPLEMENTS, vol. 4, no. 12, JPN6013030897, November 2006 (2006-11-01), pages 20, XP025026429, ISSN: 0002565518, DOI: 10.1016/S1359-6349(06)70059-3 *
RYAN,C.J. ET AL, UROLOGIC ONCOLOGY, vol. 24, no. 3, JPN6013030889, June 2006 (2006-06-01), pages 250 - 253, ISSN: 0002565514 *
SIEGEL,D.S. ET AL, BLOOD, vol. 108, no. 11, JPN6012029588, November 2006 (2006-11-01), pages 1022, ISSN: 0002246335 *
SOMLO,G. ET AL: "Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory", BLOOD, vol. 106, no. 11, JPN6013030884, 2005, pages 723A, ISSN: 0002565511 *
WRIGHT,J.D. ET AL, GYNECOLOGIC ONCOLOGY, vol. 103, no. 2, JPN6013030891, November 2006 (2006-11-01), pages 489 - 493, ISSN: 0002565517 *

Also Published As

Publication number Publication date
BRPI0717688A2 (pt) 2013-01-22
CN101547705A (zh) 2009-09-30
SI2099489T1 (sl) 2014-09-30
DK2099489T3 (da) 2014-08-18
CA2670707A1 (en) 2008-06-19
EP2099489A2 (en) 2009-09-16
WO2008073509A3 (en) 2009-01-08
KR101320198B1 (ko) 2013-10-30
NZ577058A (en) 2012-04-27
IL198852A0 (en) 2011-08-01
US20100086544A1 (en) 2010-04-08
WO2008073509A2 (en) 2008-06-19
KR20090087908A (ko) 2009-08-18
SG177891A1 (en) 2012-02-28
ZA200903489B (en) 2010-08-25
RU2482877C2 (ru) 2013-05-27
IL198852A (en) 2013-06-27
HK1131064A1 (en) 2010-01-15
EP2099489B1 (en) 2014-05-21
MX2009006202A (es) 2009-06-22
CN101547705B (zh) 2013-06-12
AU2007333565A1 (en) 2008-06-19
RU2009126588A (ru) 2011-01-20

Similar Documents

Publication Publication Date Title
CN101547705B (zh) 用于治疗新生物的组合物和方法
DK2646470T3 (en) ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
CN112203695B (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
JP7545983B2 (ja) 抗ｖｅｇｆ抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いてがんを治療する方法
JP2011504092A (ja) 血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体
KR20210006405A (ko) 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
CN119868579A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
CN110997724A (zh) 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
CA2849746A1 (en) Anti-icam-1 antibodies to treat multiple-myeloma related disorders
WO2018067819A1 (en) Compositions and methods for treatment of cancers
WO2023172906A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
JP2023025036A (ja) がんの処置のためのアベルマブの投与レジメン
CN116744970A (zh) 包含sfrp2拮抗剂的组合物和方法
JP2021535110A (ja) 併用療法
JP2021533090A (ja) 併用療法
JP7808102B2 (ja) モスネツズマブおよびポラツズマブベドチンを用いたｃｄ２０陽性増殖性障害の処置のための方法
US20240366777A1 (en) Anti-folate receptor conjugate combination therapy with bevacizumab
JP2024533439A (ja) 併用療法
AU2018203727A1 (en) Compositions and methods for treating a neoplasm
HK1131064B (en) Compositions and methods for treating a neoplasm
AU2014201911A1 (en) Compositions and methods for treating a neoplasm
RU2861262C2 (ru) Композиции и способы, содержащие антагонисты sfrp2
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
WO2024213081A1 (zh) 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途
HK40045175A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120910

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140317